China · Delayed Price · Currency is CNY Newland Pharmaceutical Statistics
Total Valuation
SHE:301277 has a market cap or net worth of CNY 3.39 billion. The enterprise value is 2.73 billion.
| Market Cap | 3.39B |
| Enterprise Value | 2.73B |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Apr 30, 2026 |
Share Statistics
SHE:301277 has 392.08 million shares outstanding. The number of shares has decreased by -1.39% in one year.
| Current Share Class | 392.08M |
| Shares Outstanding | 392.08M |
| Shares Change (YoY) | -1.39% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 63.57% |
| Owned by Institutions (%) | 1.44% |
| Float | 99.62M |
Valuation Ratios
The trailing PE ratio is 36.28.
| PE Ratio | 36.28 |
| Forward PE | n/a |
| PS Ratio | 4.62 |
| PB Ratio | 2.21 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | 107.37 |
| P/OCF Ratio | 49.62 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.18, with an EV/FCF ratio of 86.44.
| EV / Earnings | 29.36 |
| EV / Sales | 3.72 |
| EV / EBITDA | 16.18 |
| EV / EBIT | 27.32 |
| EV / FCF | 86.44 |
Financial Position
The company has a current ratio of 6.93, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.93 |
| Quick Ratio | 6.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.12 |
| Interest Coverage | 2,077.93 |
Financial Efficiency
Return on equity (ROE) is 5.98% and return on invested capital (ROIC) is 9.97%.
| Return on Equity (ROE) | 5.98% |
| Return on Assets (ROA) | 3.58% |
| Return on Invested Capital (ROIC) | 9.97% |
| Return on Capital Employed (ROCE) | 6.26% |
| Weighted Average Cost of Capital (WACC) | 5.83% |
| Revenue Per Employee | 747,934 |
| Profits Per Employee | 94,807 |
| Employee Count | 981 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 6.21 |
Taxes
In the past 12 months, SHE:301277 has paid 10.77 million in taxes.
| Income Tax | 10.77M |
| Effective Tax Rate | 10.53% |
Stock Price Statistics
The stock price has decreased by -32.75% in the last 52 weeks. The beta is 0.29, so SHE:301277's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -32.75% |
| 50-Day Moving Average | 9.82 |
| 200-Day Moving Average | 10.80 |
| Relative Strength Index (RSI) | 35.25 |
| Average Volume (20 Days) | 2,829,727 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301277 had revenue of CNY 733.72 million and earned 93.01 million in profits. Earnings per share was 0.24.
| Revenue | 733.72M |
| Gross Profit | 200.61M |
| Operating Income | 99.95M |
| Pretax Income | 102.22M |
| Net Income | 93.01M |
| EBITDA | 165.39M |
| EBIT | 99.95M |
| Earnings Per Share (EPS) | 0.24 |
Balance Sheet
The company has 663.35 million in cash and 3.73 million in debt, with a net cash position of 659.62 million or 1.68 per share.
| Cash & Cash Equivalents | 663.35M |
| Total Debt | 3.73M |
| Net Cash | 659.62M |
| Net Cash Per Share | 1.68 |
| Equity (Book Value) | 1.54B |
| Book Value Per Share | 3.92 |
| Working Capital | 899.80M |
Cash Flow
In the last 12 months, operating cash flow was 68.35 million and capital expenditures -36.76 million, giving a free cash flow of 31.59 million.
| Operating Cash Flow | 68.35M |
| Capital Expenditures | -36.76M |
| Depreciation & Amortization | 65.45M |
| Net Borrowing | -1.42M |
| Free Cash Flow | 31.59M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 27.34%, with operating and profit margins of 13.62% and 12.68%.
| Gross Margin | 27.34% |
| Operating Margin | 13.62% |
| Pretax Margin | 13.93% |
| Profit Margin | 12.68% |
| EBITDA Margin | 22.54% |
| EBIT Margin | 13.62% |
| FCF Margin | 4.31% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 2.31%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 2.31% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 84.31% |
| FCF Payout Ratio | 248.25% |
| Buyback Yield | 1.39% |
| Shareholder Yield | 3.71% |
| Earnings Yield | 2.76% |
| FCF Yield | 0.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on April 16, 2025. It was a forward split with a ratio of 1.4.
| Last Split Date | Apr 16, 2025 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |